These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35899493)

  • 21. An inhibitor of programmed death ligand 1 enhances natural killer cell-mediated immunity against malignant melanoma cells.
    Lee YS; Heo W; Choi HJ; Cho HR; Nam JH; Ki YG; Lee HR; Son WC; Park YS; Kang CD; Bae J
    PLoS One; 2021; 16(4):e0248870. PubMed ID: 33793576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort.
    Ness N; Andersen S; Khanehkenari MR; Nordbakken CV; Valkov A; Paulsen EE; Nordby Y; Bremnes RM; Donnem T; Busund LT; Richardsen E
    Oncotarget; 2017 Apr; 8(16):26789-26801. PubMed ID: 28460462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD1/PD-L1 Axis in Uro-oncology.
    Junker K; Eckstein M; Fiorentino M; Montironi R
    Curr Drug Targets; 2020; 21(13):1293-1300. PubMed ID: 32213156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer.
    Sharma M; Yang Z; Miyamoto H
    Medicine (Baltimore); 2019 Sep; 98(38):e17257. PubMed ID: 31567999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.
    Zak KM; Grudnik P; Magiera K; Dömling A; Dubin G; Holak TA
    Structure; 2017 Aug; 25(8):1163-1174. PubMed ID: 28768162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PD-L1 Mediates Dysfunction in Activated PD-1
    Concha-Benavente F; Kansy B; Moskovitz J; Moy J; Chandran U; Ferris RL
    Cancer Immunol Res; 2018 Dec; 6(12):1548-1560. PubMed ID: 30282672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
    Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
    Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy.
    Hu X; Wang J; Chu M; Liu Y; Wang ZW; Zhu X
    Mol Ther; 2021 Mar; 29(3):908-919. PubMed ID: 33388422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors.
    Almahmoud S; Zhong HA
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31546905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of regulation of PD-1 and PD-L1 expression in sepsis.
    Zhang T; Yu-Jing L; Ma T
    Front Immunol; 2023; 14():1029438. PubMed ID: 36969168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma.
    Yokoyama S; Miyoshi H; Nakashima K; Shimono J; Hashiguchi T; Mitsuoka M; Takamori S; Akagi Y; Ohshima K
    Clin Cancer Res; 2016 Sep; 22(18):4727-34. PubMed ID: 27166394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spatiotemporal Changes in Checkpoint Molecule Expression.
    Li W; Qie J; Zhang Y; Chang J
    Adv Exp Med Biol; 2020; 1248():167-200. PubMed ID: 32185711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of Programmed Death Receptor 1 (PD-1) Gene and Its Ligand (PD-L1) in Patients with Laryngeal Cancer.
    Kowalski A; Malinowska K; Olszewski J; Zielińska-Bliźniewska H
    Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome.
    Veloza L; Teixido C; Castrejon N; Climent F; Carrió A; Marginet M; Soldini D; González-Farré B; Ribera-Cortada I; Lopez-Guillermo A; González-Barca E; Sierra A; Herrera M; Gómez C; Garcia A; Balagué O; Campo E; Martinez A
    Histopathology; 2019 Dec; 75(6):799-812. PubMed ID: 30861172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma.
    Kamamoto D; Ohara K; Kitamura Y; Yoshida K; Kawakami Y; Sasaki H
    J Neurooncol; 2018 Sep; 139(2):251-259. PubMed ID: 29675794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring the role of programmed cell death protein 1 and its ligand 1 in eye diseases.
    Wang X; Wu M; Cao Y; Zhang Z; Guo F; Li X; Zhang Y
    Crit Rev Clin Lab Sci; 2019 Jan; 56(1):18-32. PubMed ID: 30602320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased Expression of PD-1 and PD-L1 in Patients With Laryngotracheal Stenosis.
    Davis RJ; Lina I; Ding D; Engle EL; Taube J; Gelbard A; Hillel AT
    Laryngoscope; 2021 May; 131(5):967-974. PubMed ID: 32557663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of phenyl-linked symmetric small molecules as inhibitors of the programmed cell death-1/programmed cell death-ligand 1 interaction.
    Wu Y; Zhang Y; Guo Y; Pan Z; Zhong S; Jin X; Zhuang W; Chen S; Gao J; Huang W; Dong X; Che J
    Eur J Med Chem; 2021 Nov; 223():113637. PubMed ID: 34147746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of PD-L1 Regulation in Malignant and Virus-Infected Cells.
    Farrukh H; El-Sayes N; Mossman K
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34063096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.